Carmell Therapeutics Corporation Net Assets
Carmell Therapeutics Corporation net assets. Based on the latest financial reports, Carmell Therapeutics Corporation (CTCX) has net assets worth $-3.81 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.34 Million) and total liabilities ($7.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Carmell Therapeutics Corporation (CTCX) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.81 Million |
| % of Total Assets | -114.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Carmell Therapeutics Corporation (2021–2024)
Net assets of Carmell Therapeutics Corporation from 2021 to 2024. This chart illustrates how Carmell Therapeutics Corporation's net assets have evolved over time, based on quarterly financial data. See Carmell Therapeutics Corporation balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Carmell Therapeutics Corporation (2021–2024)
The table below shows the annual net assets of Carmell Therapeutics Corporation from 2021 to 2024. For live market cap and overall valuation, see CTCX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-4.71 Million | -119.04% |
| 2023-12-31 | $24.75 Million | +165.49% |
| 2022-12-31 | $-37.79 Million | -27.77% |
| 2021-12-31 | $-29.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Carmell Therapeutics Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3609720600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Carmell Therapeutics Corporation Net Assets Breakdown (December 2024)
Carmell Therapeutics Corporation net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.09K | % |
| Other Components | $64.16 Million | % |
| Total Equity | $-4.71 Million | 100.00% |
Carmell Therapeutics Corporation Competitors by Market Cap
The table below lists competitors of Carmell Therapeutics Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UNITH LTD.
F:CM30
|
$4.61 Million |
|
CARLSON INV. ZY 13
F:2HB
|
$4.61 Million |
|
Strategem Capital Corp
V:SGE
|
$4.62 Million |
|
Traws Pharma Inc
NASDAQ:TRAW
|
$4.62 Million |
|
Kane Biotech Inc
V:KNE
|
$4.60 Million |
|
Resources & Energy Group Ltd
AU:REZ
|
$4.60 Million |
|
OLB Group Inc
NASDAQ:OLB
|
$4.60 Million |
|
Acurx Pharmaceuticals LLC
NASDAQ:ACXP
|
$4.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Carmell Therapeutics Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 24,749,010 to -4,712,662, a change of -29,461,672 (-119.0%).
- Net loss of 10,368,261 reduced equity.
- New share issuances of 2,687,225 increased equity.
- Other factors decreased equity by 21,780,636.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.37 Million | -220.01% |
| Share Issuances | $2.69 Million | +57.02% |
| Other Changes | $-21.78 Million | -462.17% |
| Total Change | $- | -119.04% |
Book Value vs Market Value Analysis
This analysis compares Carmell Therapeutics Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-1.50 | $0.15 | x |
| 2022-12-31 | $-1.91 | $0.15 | x |
| 2023-12-31 | $1.19 | $0.15 | x |
| 2024-12-31 | $-0.23 | $0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Carmell Therapeutics Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20605.47%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-15.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.52 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.27 Million |
| 2023 | -62.41% | 0.00% | 0.00x | 2.58x | $-17.92 Million |
| 2024 | 0.00% | -20605.47% | 0.03x | 0.00x | $-9.90 Million |
Industry Comparison
This section compares Carmell Therapeutics Corporation's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $626,399,091
- Average return on equity (ROE) among peers: -586.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Carmell Therapeutics Corporation (CTCX) | $-3.81 Million | 0.00% | N/A | $4.61 Million |
| Acme United Corporation (ACU) | $22.89 Million | 19.52% | 0.98x | $158.51 Million |
| Instinct Bio Technical Company Holdings Inc. Ordinary Shares (BIOT) | $2.31 Million | 23.61% | 0.48x | $5.19 Million |
| Bruush Oral Care Inc. (BRSHF) | $163.14K | -5449.60% | 11.70x | $20.19K |
| Park Ha Biological Technology Co., Ltd. (BYAH) | $1.01 Million | 84.15% | 1.24x | $12.69 Million |
| Church & Dwight Company Inc (CHD) | $153.90 Million | 3.96% | 0.92x | $24.49 Billion |
| Colgate-Palmolive Company (CL) | $1.36 Billion | 23.54% | 2.05x | $74.35 Billion |
| The Clorox Company (CLX) | $-135.00 Million | 0.00% | 0.00x | $10.75 Billion |
| Coty Inc (COTY) | $4.23 Billion | 12.00% | 1.99x | $2.51 Billion |
| Big Tree Cloud Holdings Limited Ordinary Shares (DSY) | $-4.58 Million | 0.00% | 0.00x | $4.07 Million |
About Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on … Read more